Piperacillin-Tazobactam: an update for clinical use

Autores

  • Alice R. Correa e Castro Costa Faculdade de Medicina, Universidade Federal de Viçosa, Viçosa, MG, Brazil. https://orcid.org/0000-0003-4517-9713
  • Andréia Patrícia Gomes Departamento de Medicina e Enfermagem, Universidade Federal de Viçosa. Viçosa, MG, Brazil. https://orcid.org/0000-0002-5046-6883
  • Eduardo Vinícius V. Varejão Departamento de Química, Universidade Federal de Viçosa. Viçosa, MG, Brazil https://orcid.org/0000-0002-1830-725X
  • Romario Brunes Faculdade de Medicina, Universidade Federal de Viçosa, Viçosa, MG, Brazil. https://orcid.org/0000-0001-6504-8927
  • Walter Tavares Faculdade de Medicina, Centro Universitário Serra dos Órgãos, Teresópolis, RJ, Brazil.
  • Luiz Alberto Santana Departamento de Medicina e Enfermagem, Universidade Federal de Viçosa, Viçosa, MG, Brazil.
  • Rodrigo Siqueira-Batista Escola de Medicina, Faculdade Dinâmica do Vale do Piranga, Ponte Nova, MG, Brazil.

DOI:

https://doi.org/10.12957/bjhbs.2024.85197

Resumo

Introduction: Piperacillin-tazobactam, a broad-spectrum penicillin, is an important option in the treatment of infections, especially in critically ill patients who exhibit high rates of resistance to various antimicrobial agents. Understanding this medication and updates on its clinical use is of paramount significance to guide precise therapeutic choices aimed at the optimization of patient care. Objective: To describe the main pharmacological and therapeutic aspects of piperacillin-tazobactam, highlighting its clinical application and updates related to its use. Methods: A narrative review of the literature was conducted in order to provide an update on the most relevant aspects related to piperacillin-tazobactam, including (1) a brief history; (2) chemical structure; (3) mechanism of action; (4) resistance mechanisms; (5) spectrum; (6) major clinical uses; and (7) adverse effects. Results: The safe use of piperacillin-tazobactam requires rapid testing for antimicrobial resistance patterns, thus discouraging its empirical use in cases of ESBL-producing microorganisms. In patients undergoing renal replacement therapy, antibiotic goals must be established promptly. For critically ill patients, monitoring pharmacodynamic and pharmacokinetic variability is essential. Conclusion: Piperacillin-tazobactam remains a vital drug in the management of critically ill patients, while requiring constant updates. In addition, further studies are required, especially concerning its continuous use and the selection of alternatives to carbapenem-resistant medications. 

Downloads

Não há dados estatísticos.

Biografia do Autor

Rodrigo Siqueira-Batista, Escola de Medicina, Faculdade Dinâmica do Vale do Piranga, Ponte Nova, MG, Brazil.

Departamento de Medicina e Enfermagem, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.  

Downloads

Publicado

2024-07-12

Como Citar

1.
R. Correa e Castro Costa A, Gomes AP, V. Varejão EV, Brunes R, Tavares W, Santana LA, et al. Piperacillin-Tazobactam: an update for clinical use. BJHBS [Internet]. 12º de julho de 2024 [citado 2º de maio de 2025];23(1). Disponível em: https://www.e-publicacoes.uerj.br/bjhbs/article/view/85197

Edição

Seção

Revisão de Literatura

Artigos mais lidos pelo mesmo(s) autor(es)